Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by Oceanison Feb 19, 2023 10:55pm
186 Views
Post# 35294682

StudyThousands of Twins Dispels Cannabis Gateway Drug Theory

StudyThousands of Twins Dispels Cannabis Gateway Drug Theory

CU Study on Thousands of Twins Dispels Cannabis Gateway Drug Theory

CU's ongoing study on twins and cannabis provides data for research across the country.Unsplash/Shelby Ireland
Much to the chagrin of the "Just Say No" crowd, that theory about cannabis being a gateway drug just doesn't fly, according to research coming out of the University of Colorado Boulder.

In 2018, CU researchers partnered with the University of Minnesota's Center for Twin Family Research to study sets of twins who live in Colorado, where recreational cannabis sales have been legal since 2014, and some who live in Minnesota, where recreational pot is still banned. Over the next few years, researchers asked around 2,500 sets of twins, both users and non-users, an extensive set of questions to assess the effects of marijuana legalization.

After four years of data collection and analysis, the researchers recently reported that residents in both the legal and non-legal states had around the same rate of substance abuse or cognitive, psychological, social, relationship or financial problems. And cannabis use may even reduce alcohol-related problems, according to their findings.

To learn more about the results, we interviewed lead researcher 

<< Previous
Bullboard Posts
Next >>